David G. Macmanus

Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute Of Neurology
London, ENG WC1N3BG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial.

Investigating the treatment of vascular risk with simvastatin in secondary progressive multiple sclerosis: analysis from the MS-STAT2 randomized controlled trial.

Journal: Brain communications

Published: November 25, 2025

The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy.

The Cambridge Centre for Myelin Repair trial Two (CCMR Two): a trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy.

Journal: Trials

Published: March 10, 2025

Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.

Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: August 08, 2024

Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial.

Investigating the relationship between thalamic iron concentration and disease severity in secondary progressive multiple sclerosis using quantitative susceptibility mapping: Cross-sectional analysis from the MS-STAT2 randomised controlled trial.

Journal: Neuroimage. Reports

Published: May 27, 2024

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.

Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.

Journal: Journal of neurology

Published: January 03, 2024

Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.

Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome.

Journal: Brain : a journal of neurology

Published: August 08, 2023

Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.

Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis.

Journal: European journal of neurology

Published: May 31, 2023

Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.

Longitudinal Metabolite Changes in Progressive Multiple Sclerosis: A Study of 3 Potential Neuroprotective Treatments.

Journal: Journal of magnetic resonance imaging : JMRI

Published: May 29, 2023

Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.

Cardiovascular risk factors in secondary progressive multiple sclerosis: A cross-sectional analysis from the MS-STAT2 randomized controlled trial.

Journal: European journal of neurology

Published: March 29, 2023

Remyelination varies between and within lesions in multiple sclerosis following bexarotene.

Remyelination varies between and within lesions in multiple sclerosis following bexarotene.

Journal: Annals of clinical and translational neurology

Published: June 16, 2022

S-duct flow distortion with non-uniform inlet conditions.

S-duct flow distortion with non-uniform inlet conditions.

Journal: Proceedings of the Institution of Mechanical Engineers. Part G, Journal of aerospace engineering

Published: August 10, 2021

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 09, 2021

Showing 1-12 of 25

Last Updated: 09/26/2026